# 該公司表示，65名患者的研究未達預定門檻。

*biotech · news · 2026-05-29 · Reuters*

## Key points

- tebapivat低風險骨髓增生異常症候群試驗未達預定的開發推進門檻。
- tebapivat在低風險骨髓增生異常症候群試驗中整體耐受良好，未發現新的安全性問題。
- tebapivat在鐮刀型細胞病的早期臨床結果預計將於2026年下半年公布。
- 已獲批准的藥物Aqvesme現正被考慮作為潛在的鐮刀型細胞病治療選項。

Its shares fell 1.7% in morning trading. Sign up here. The company said the 65-patient study did not meet ​the predefined threshold for developing the drug, named tebapivat, to ​treat lower-risk myelodysplastic syndromes (LR-MDS), a group of cancers in which the ⁠bone marrow does not make enough healthy blood cells. The ​diseases can sometimes progress to leukemia. The trial tested three once-daily oral ​doses of tebapivat over 24 weeks in patients with LR-MDS and anemia, many of whom had already received other treatments. The main goal was to ​find whether patients could go at least eight weeks without ​needing a blood transfusion. J.P. Morgan analyst Tessa Romero said the outcome wasn’t surprising, ‌as ⁠the trial was risky from the beginning due to the variability of the diseases and the heavily pre-treated patient group. The drugmaker said tebapivat was generally well-tolerated, with no new safety concerns. Tebapivat belongs ​to a class ​of medicines called ⁠pyruvate kinase (PK) activators, which boost an enzyme in red blood cells to help them function more ​effectively. The Cambridge, Massachusetts-based company said it will continue ​testing the ⁠drug for sickle cell disease, with early results expected in the second half of 2026. Aqvesme, the company's drug to treat some inherited ⁠blood ​disorders, is being rolled out after it was ​approved last year. It could also have the potential to treat sickle cell disease, ​Romero said. Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Sahal Muhammed

**Companies:** Company
**Countries:** United States, India

[Read the full story on Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/agios-scraps-blood-cancer-drug-program-after-study-miss-2026-05-29/)

---

Canonical: https://newsio.io/zh-TW/n/ccc97e3f-7217-4738-a0d8-a4e51cf0d1e4/651-7tebapivat
Summarized by Newsio from Reuters. https://newsio.io/how-it-works